Another immuno-cancer drug with CTLA-4 inhibitory mechanism is expected to be introduced in Korea. According to related industries, AstraZeneca Korea has submitted an application for domestic permission for CTLA-4 inhibitor Imjudo, a partner in combination therapy for PD-L1 inhibitor Impinzi. The combination therapy of Impinzi and Imjudo was approved by the U.S. FDA last month as an irreversible hepatocellular carcinoma treatment. Combination therapy is the only dual immuno-cancer therapy allowed to date for the first round of liver cancer.

Combination therapy is a STRIDE (Single Tremelimumab Regular Interval Durvalumab) strategy in which Impinzi is additionally administered at regular intervals every 4